Organix, a Massachusetts based corporation established in 1986, is a pioneer of Contract Research in Synthetic Organic and Medicinal Chemistry in the United States. Organix is recognized internationally as a premier provider of outstanding services at the discovery end of the drug development pathway. We provide Custom Synthesis of molecules in all structural classes, Design and Synthesis of New Chemical Entities, Structure Activity Relationship Studies, Hit-to-Lead Studies, and Development and Optimization of Synthetic Procedures and Design and Synthesis of Drug Conjugates in which active NCEs are tethered to HRP, PEG, HPMA-polymers, HPMA-copolymers, or other large molecules. These tethered NCEs can also be designed to cleave and release the NCE in situ.